3650 results for «382»
3650 results
Has the 2023 ESC-EACTS guideline review on left main changed my practice?
15 May 2024 – From EuroPCR 2024
Watch this session if you wish to learn why the 2019 guidelines were revised, how to apply the updated recommendations in clinical settings through case examples, and the criteria for selecting patients with left main stenosis for PCI versus CABG.
The session includes detailed presentations on...
The uncrossable lesion
16 May 2024 – From EuroPCR 2024
This session delves into the challenges of dealing with uncrossable and heavily calcified coronary lesions. It features a variety of cases showcasing the use of specialized techniques and tools, such as the excimer laser, to overcome these obstacles. The session emphasizes the importance of troubleshooting, utilizing...
When mitral valve intervention goes wrong
16 May 2024 – From EuroPCR 2024
This session examines various complications that can arise during mitral valve interventions, such as iatrogenic aortic root perforation, unexpected leakage, and other challenging scenarios. The presenters share their experiences in managing these complications and the strategies they employed to address them. The session emphasizes the importance...
TAVI Hotline: new devices, new approaches
15 May 2024 – From EuroPCR 2024
POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?
02 Sep 2024
Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials
14 Nov 2021
Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.
Author
Evidence base: current data on TAVI durability and long-term outcomes
18 Jun 2026
This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.
Author
Author
ESC/EACTS Valvular Heart Disease Guidelines 2021: updates from the 2017 Guidelines
29 Aug 2021
There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...
Author
Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)
30 Oct 2024
Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.
Author
